We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease

MedXY Editorial Team•Oct 3, 2025•Neurology
medicationmortality riskParkinson disease

Background and Objectives

Currently, there are no available treatments that can effectively halt or slow the progression of Parkinson disease (PD). This study aimed to identify new candidates for drug repurposing among existing prescription medications that might modify the disease course in patients with PD.

Methods

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Long-Term Road Traffic Noise Exposure and Its Association with Parkinson Disease Risk: Insights from a Danish Nationwide Cohort StudyA nationwide Danish study links prolonged residential road traffic noise exposure with increased Parkinson disease risk, highlighting the protective effect of having a quiet building facade.Jul 22, 2026Continuous Glucose Monitoring and Survival Benefits in Diabetic Veterans on Dialysis: Insights from a Nationwide CohortAmong U.S. veterans with diabetes on dialysis, continuous glucose monitoring (CGM) use was associated with significantly lower mortality risk compared to non-CGM use, highlighting CGM’s potential to improve survival in this high-risk Jul 1, 2026Why Prevalence Is Rising Differently in Parkinson Disease, Multiple Sclerosis, and Motor Neuron DiseasesA large Sweden-France analysis suggests rising MS prevalence is mainly survival-driven, increasing MND prevalence reflects growing incidence, and PD prevalence rises modestly through mixed demographic and survival effects.Jun 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial
In a phase 3 trial, once-daily tavapadon improved motor symptoms in people with early Parkinson disease and was generally well tolerated, with nausea, headache, and dizziness as the most common side effects.
May 20, 2026
Corticostriatal Connectivity Reorganizes Before and After Motor Decline in Parkinson DiseaseResting-state MRI and PET data suggest that corticostriatal networks remodel across nigrostriatal degeneration in Parkinson disease, with posterior caudate hyperconnectivity preceding major motor decline and posterior putaminal disconnectioApr 19, 2026
Diabetic Retinopathy Severity Predicts Mortality Risk: Insights from the SOURCE ConsortiumA retrospective cohort study of 524,687 diabetic patients reveals that increasing severity of diabetic retinopathy correlates with significantly higher mortality risk, with proliferative DR patients showing a 128% increased hazard of death Apr 11, 2026